Related Experiment Videos

Protective efficacy of a whole cell pertussis vaccine

M Blennow1, P Olin, M Granström

  • 1Karolinska Institute, Department of Paediatrics, Sach's Children's Hospital, Stockholm, Sweden.

Insights

A whole cell pertussis vaccine trial in Sweden showed 80% efficacy in preventing pertussis (whooping cough) in infants. This demonstrates the vaccine

Area of Science:

  • Pediatrics
  • Immunology
  • Vaccinology

Background:

  • Pertussis (whooping cough) remains a significant public health concern.
  • Evaluating vaccine efficacy is crucial for disease prevention strategies.

Purpose of the Study:

  • To assess the efficacy of a plain whole cell pertussis vaccine in Swedish infants.
  • To compare pertussis incidence between vaccinated and unvaccinated children.

Main Methods:

  • A non-blinded trial involving 525 vaccinated infants and 615 unvaccinated controls.
  • Infants received three doses of whole cell pertussis vaccine or served as controls.
  • Follow-up period of 18 months to record pertussis cases.

Main Results:

  • The pertussis attack rate was 1.5% in vaccinated infants versus 7.6% in unvaccinated controls.
  • The vaccine demonstrated an estimated efficacy of 80% (95% CI: 58-90).
  • A statistically significant reduction in pertussis cases was observed in the vaccinated group (p < 0.001).

Conclusions:

  • The plain whole cell pertussis vaccine is highly effective in preventing pertussis in infants.
  • The vaccine's efficacy is comparable to findings from earlier trials.
  • This study supports the continued use of whole cell pertussis vaccines for infant immunization programs.

Related Concept Videos